BLFS - BioLife Solutions, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

BioLife Solutions, Inc.

3303 Monte Villa Parkway
Suite 310
Bothell, WA 98021
United States
425-402-1400
http://www.biolifesolutions.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees54

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael P. RicePres, CEO & Director578.9kN/A1963
Mr. Roderick de GreefCFO, COO & Sec.402.5kN/A1960
Dr. Aby J. MathewChairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer419.75kN/A1972
Mr. Kevin O'DonnellVP of Cold Chain Standards, Practices & ComplianceN/AN/AN/A
Mr. Todd BerardChief Marketing OfficerN/AN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Corporate Governance

BioLife Solutions, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.